Corient Private Wealth
PACB icon

Corient Private Wealth’s Pacific Biosciences PACB Stock Holding History

Corient Private Wealth’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7K Buy
17,706
+848
+5% +$1.23K ﹤0.01% 2964
2026
Q1 		$21.3K Buy
+16,858
New +$30.2K ﹤0.01% 2780

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Corient Private Wealth's PACB Position: Q2 2026 in Review

Corient Private Wealth increased its Pacific Biosciences (PACB) stake by 5% in Q2 2026, buying an estimated $1.23K and bringing the position to 17,706 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

Corient Private Wealth first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Corient Private Wealth held 17,706 shares of Pacific Biosciences worth $29.7K as of Q2 2026.
  • Corient Private Wealth bought 848 Pacific Biosciences shares in Q2 2026, an estimated $1.23K.
  • Pacific Biosciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2964 holding.
  • Corient Private Wealth first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.